The stock of LENZ Therapeutics Inc. (NASDAQ: LENZ) has decreased by -3.83 when compared to last closing price of 23.50.Despite this, the company has seen a loss of -6.30% in its stock price over the last five trading days. globenewswire.com reported 2024-08-14 that Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for LNZ100 for the treatment of presbyopia
Is It Worth Investing in LENZ Therapeutics Inc. (NASDAQ: LENZ) Right Now?
LENZ has 36-month beta value of 0.50. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LENZ is 18.30M, and currently, short sellers hold a 10.56% ratio of that float. The average trading volume of LENZ on August 16, 2024 was 186.56K shares.
LENZ’s Market Performance
LENZ’s stock has seen a -6.30% decrease for the week, with a 3.62% rise in the past month and a 42.68% gain in the past quarter. The volatility ratio for the week is 6.90%, and the volatility levels for the past 30 days are at 6.52% for LENZ Therapeutics Inc. The simple moving average for the past 20 days is -3.59% for LENZ’s stock, with a 42.26% simple moving average for the past 200 days.
Analysts’ Opinion of LENZ
Many brokerage firms have already submitted their reports for LENZ stocks, with H.C. Wainwright repeating the rating for LENZ by listing it as a “Buy.” The predicted price for LENZ in the upcoming period, according to H.C. Wainwright is $38 based on the research report published on August 12, 2024 of the current year 2024.
Leerink Partners gave a rating of “Outperform” to LENZ, setting the target price at $32 in the report published on April 15th of the current year.
LENZ Trading at 11.13% from the 50-Day Moving Average
After a stumble in the market that brought LENZ to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.30% of loss for the given period.
Volatility was left at 6.52%, however, over the last 30 days, the volatility rate increased by 6.90%, as shares surge +4.82% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +53.95% upper at present.
During the last 5 trading sessions, LENZ fell by -6.30%, which changed the moving average for the period of 200-days by +37.39% in comparison to the 20-day moving average, which settled at $23.49. In addition, LENZ Therapeutics Inc. saw 82.26% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LENZ starting from Chevallard Daniel R., who purchase 3,188 shares at the price of $15.68 back on May 14 ’24. After this action, Chevallard Daniel R. now owns 3,188 shares of LENZ Therapeutics Inc., valued at $49,988 using the latest closing price.
MCCOLLUM JAMES W, the Director of LENZ Therapeutics Inc., purchase 31,332 shares at $15.99 during a trade that took place back on May 13 ’24, which means that MCCOLLUM JAMES W is holding 525,565 shares at $501,093 based on the most recent closing price.
Stock Fundamentals for LENZ
The total capital return value is set at -0.33. Equity return is now at value -34.67, with -29.53 for asset returns.
Based on LENZ Therapeutics Inc. (LENZ), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -157.67.
Currently, EBITDA for the company is -70.7 million with net debt to EBITDA at 3.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 23.23.
Conclusion
To put it simply, LENZ Therapeutics Inc. (LENZ) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
